Pluri Inc. (PLUR) Q1 2025 (Ended Sept 30, 2024) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended September 30, 2024 (Q1 of fiscal year 2025). Pluri Inc. is a biotechnology company operating in regenerative medicine, immunotherapy, food technology (via Ever After Foods), and agricultural technology. The company utilizes a proprietary 3D cell expansion platform and operates a Contract Development and Manufacturing Organization (CDMO). The filing reflects a 1-for-8 reverse share split effective April 1, 2024.
Key Financial Metrics
| Metric | Q1 2025 (Sep 30, 2024) | Q1 2024 (Sep 30, 2023) |
|---|---|---|
| Revenue | $326,000 | $54,000 |
| Gross Profit | $200,000 | $54,000 |
| Net Loss | $(6,036,000) | $(5,098,000) |
| Net Loss Attributable to Shareholders | $(5,882,000) | $(4,961,000) |
| Loss Per Share (Basic & Diluted) | $(1.08) | $(0.96) |
| Cash & Equivalents | $3,198,000 | $5,253,000 |
| Total Cash & Deposits | $26,677,000 | $6,159,000 |
| Working Capital | $22,449,000 | N/A |
| Long-Term Debt (EIB Loan) | $25,365,000 | N/A |
Note: Total cash includes short-term bank deposits ($22.5M) and restricted cash/deposits. The company reported a negative cash flow from operating activities of $4.1M for the quarter.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 504% to $326,000, driven by new CDMO services and AgTech collaborations, compared to $54,000 in the prior year.
- Net Loss Expansion: Net loss increased by 18% to $6.0M. This was primarily due to a swing in "Other financial income (expenses)" from a $493k gain in 2023 to a $621k expense in 2024, driven by foreign currency translation losses on the Euro-denominated EIB loan.
- Operating Expenses: Net R&D expenses decreased slightly (3%) to $2.9M due to headcount reductions (9 fewer employees) and increased grant participation. G&A expenses increased 3% to $2.5M, largely due to the reinstatement of the CEO's full cash salary and performance bonuses.
- Liquidity: While cash and cash equivalents decreased, total liquid assets (including short-term deposits) remain robust at $26.7M, providing a working capital surplus of $22.4M.
Outlook, Risks, and Management Commentary
- Outlook: Management believes current resources are sufficient to fund operations for at least the next 12 months. The company does not expect significant product sales revenue in the next year, relying instead on CDMO services, collaborations, and grants.
- Strategic Developments:
- Ever After Foods: Completed a $10M private placement in June 2024; Pluri retains ~69% ownership.
- Immunotherapy: Launched a novel allogeneic MAIT cell platform for solid tumors in May 2024.
- Grants: Received a $1.4M extension from NIAID for H-ARS research and a new $148k grant from the Israeli Innovation Authority (IIA) for MAIT cell development.
- Risks & Contingencies:
- Geopolitical Risk: Principal R&D and manufacturing facilities are in Haifa, Israel. Escalating conflict with Hamas, Hezbollah, and Iran poses a risk of operational disruption, employee mobilization (3 employees currently on active duty), and economic instability.
- Debt Obligations: The company holds a €20M loan from the European Investment Bank (EIB) due June 2026. It bears 4% interest and requires royalty payments of 0.2% to 2.3% of consolidated revenues starting in FY2024.
- Nasdaq Compliance: The company received a deficiency letter in May 2024 regarding minimum shareholders' equity but regained compliance as of September 26, 2024.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $26.7M cash position against the ~$6M quarterly burn rate, considering the lack of significant product revenue.
- Geopolitical Exposure: Assess the potential impact of the ongoing conflict in Israel on the Haifa-based manufacturing facility and employee availability.
- EIB Loan Terms: Review the royalty obligations (up to 2.3% of revenue) and the maturity date (June 2026) to understand future cash outflow requirements.
- Revenue Quality: Analyze the sustainability of the $326k revenue, which is currently driven by CDMO services and AgTech collaborations rather than core therapeutic product sales.
- Equity Dilution: Monitor the "At-the-Market" (ATM) sales agreement, under which the company can sell up to $10M of shares, and recent share issuances for compensation.